×

Gordagen Pharmaceuticals Engages Ascendiant Capital Markets for Investment Banking Services

MELBOURNE, Australia, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing and commercializing pharmaceuticals and nutraceuticals based on tocotrienols, today announced its engagement with Ascendiant Capital Markets LLC to serve as the Company's United States investment banker and corporate financial advisor.

Dr. Glenn Tong, CEO and Managing Director of Gordagen Pharmaceuticals, commented, "We expect our relationship with Ascendiant Capital to enable Gordagen to strengthen our financing opportunities and build institutional investor interest in the US as we execute our growth strategy and drive our products to market. In addition, by engaging with a strong US investment bank, we believe we will be able to add to an already solid pedigree of international institutional investors that understand the value opportunity for Gordagen. We have been most impressed with the industry knowledge of Dr. Brian Davies and Dr. Chris Gayde, two Managing Directors of Ascendiant, and look forward to working with them and their team."

Felda Wellness Corporation, the cornerstone investor in Gordagen Pharmaceuticals' Series A financing round completed in January 2014, has expressed strong support for this Series B financing round.

"We have been very pleased with Gordagen Pharmaceuticals' achievements to date, which include the establishment of a cGMP manufacturing capability, the commencement of an ICH-GCP clinical development program and putting in place a robust strategy to bring a deep portfolio of high value nutraceuticals and prescription medicines to market," commented Mr. Mohd Nasir bin Shafion, the Chief Executive Officer of Felda Wellness Corporation.

Separately, Gordagen expects to prepare for an initial public offering (IPO) in the United States and a listing on the Nasdaq Stock Exchange.

About Gordagen Pharmaceuticals Pty Ltd

Gordagen Pharmaceuticals is a privately-held Australian company developing and commercializing evidence-based prescription medicines and nutraceuticals based on natural tocotrienols, found in vitamin E. The Company has developed a novel approach to delivering highly potent tocotrienols to target tissues using its proprietary and patented MELT3 delivery technology. The Company is focusing on tocotrienols with wide therapeutic potential, for the treatment of heart health, muscle soreness and exercise endurance and a range of indications with unmet medical needs (ie. Hyperlipidemia, hypertension and diabetes) www.gordagen.com.

About Ascendiant Capital Markets

Ascendiant Capital Markets LLC is registered with the U.S. Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the Financial Industry Regulatory Authority (FINRA) and Securities Investor Protection Corporation (SIPC). Ascendiant works on a best efforts basis with all clients.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

CONTACT: Investor and Media Inquiries: Paris Brooke - Australia and Asia Ph: +61 (0) 407 715 574 David Burke, The Ruth Group - Americas, Europe Ph: +1 646-536-7009 Ascendiant Capital Markets Contact: Chris Gayde Ph: +1 949-259-4918 Email: cgayde@ascendiant.com

Source:Gordagen Pharmaceuticals